CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| A031702 | Alliance | A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC) | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1806 | SWOG | Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| CALGB-90206 | CALGB | A Randomized Phase III Trial of Interferon Alfa-2B or Interferon Alfa-2B Plus Bevacizumab in Patients with Advanced Renal Carcinoma | Adult CIRB - Late Phase Emphasis | Completed |
| A091902 | Alliance | A Multicenter Phase II Trial of Paclitaxel with and without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| NSABP-C-09 | NSABP | A Phase III Clinical Trial Comparing Oxaliplatin; Capecitabine; and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients with Resected or Ablated Liver Metastases from Colorectal Cancer. | Adult CIRB - Late Phase Emphasis | Completed |
| GOG-0250 | GOG | A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297 | Adult CIRB - Late Phase Emphasis | Completed |
| E2810 | ECOG | Randomized; Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA7211 | ECOG-ACRIN | A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2) | Adult CIRB - Late Phase Emphasis | Available to Open |
| EAA173 | ECOG-ACRIN | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | Adult CIRB - Late Phase Emphasis | Available to Open |
| A031803 | Alliance | Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |